Jennifer R Brown1, Mehdi Hamadani2, John Hayslip3, Ann Janssens4, Nina Wagner-Johnston5, Oliver Ottmann6, Jon Arnason7, Hervé Tilly8, Michael Millenson9, Fritz Offner10, Nashat Y Gabrail11, Siddhartha Ganguly12, Sikander Ailawadhi13, Siddha Kasar14, Arnon P Kater15, Jeanette K Doorduijn16, Lei Gao17, Joanne J Lager17, Bin Wu17, Coumaran Egile18, Marie José Kersten15. 1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Jennifer_brown@dfci.harvard.edu. 2. Department of Medicine, West Virginia University, Morgantown, WV, USA; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Markey Cancer Center, University of Kentucky, Lexington, KY, USA. 4. Department of Haematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium. 5. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA. 6. Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK. 7. Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 8. Department of Haematology and INSERM U1245, Centre Henri Becquerel, Rouen University, Rouen, France. 9. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 10. Dienst Hematologie, Universitair Ziekenhuis Gent, Gent, Belgium. 11. Gabrail Cancer Center, Canton, OH, USA. 12. Division of Hematology/Oncology, University of Kansas Medical Center, Kansas City, KS, USA. 13. Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA. 14. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 15. Department of Hematology, Academic Medical Center, Amsterdam, Netherlands; Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands. 16. Erasmus MC Cancer Institute, Rotterdam, Netherlands. 17. Sanofi, Cambridge, MA, USA. 18. Sanofi Oncology, Vitry sur Seine, France.
Abstract
BACKGROUND: Patients with relapsed or refractory lymphoma or chronic lymphocytic leukaemia have a poor prognosis. Therapies targeting more than one isoform of PI3K, as well as mTOR, might increase antitumour activity. We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. METHODS: We did a non-randomised, open-label, phase 2 trial at 30 oncology clinics in the USA, Belgium, Germany, France, the Netherlands, and Australia. Patients aged 18 years or older with Eastern Cooperative Oncology Group (EGOG) performance status score of 2 or lower and relapsed or refractory mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma were enrolled and treated with voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity. The primary endpoint was the proportion of patients in each disease-specific cohort who achieved an overall response, defined as a complete response or partial response. All patients who received more than 4 weeks of treatment and who completed a baseline and at least one post-baseline tumour assessment were analysed for efficacy and all patients were analysed for safety. This study is registered with ClinicalTrials.gov, number NCT01403636, and has been completed. FINDINGS: Between Oct 19, 2011, and July 24, 2013, 167 patients were enrolled (42 with mantle cell lymphoma, 47 with follicular lymphoma, 42 with diffuse large B-cell lymphoma, and 36 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The median number of previous anticancer regimens was three (IQR 2-4) for patients with lymphoma and four (2-5) for patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Of 164 patients evaluable for efficacy, 30 (18·3%) achieved an overall response (partial, n=22; complete, n=8); 19 (41·3%) of 46 with follicular lymphoma, five (11·9%) of 42 with mantle cell lymphoma, two (4·9%) of 41 with diffuse large B-cell lymphoma, and four (11·4%) of 35 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The safety profile was consistent with that of previous studies of voxtalisib. The most frequently reported adverse events were diarrhoea (in 59 [35%] of 167 patients), fatigue (in 53 [32%]), nausea (in 45 [27%]), pyrexia (in 44 [26%,]), cough (in 40 [24%]), and decreased appetite (in 35 [21%]). The most frequently reported grade 3 or worse adverse events were anaemia (in 20 [12%] of 167 patients), pneumonia (in 14 [8%]), and thrombocytopenia (in 13 [8%]). Serious adverse events occurred in 97 (58·1%) of 167 patients. INTERPRETATION: Voxtalisib 50 mg given orally twice daily had an acceptable safety profile, with promising efficacy in patients with follicular lymphoma but limited efficacy in patients with mantle cell lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. FUNDING: Sanofi.
BACKGROUND:Patients with relapsed or refractory lymphoma or chronic lymphocytic leukaemia have a poor prognosis. Therapies targeting more than one isoform of PI3K, as well as mTOR, might increase antitumour activity. We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. METHODS: We did a non-randomised, open-label, phase 2 trial at 30 oncology clinics in the USA, Belgium, Germany, France, the Netherlands, and Australia. Patients aged 18 years or older with Eastern Cooperative Oncology Group (EGOG) performance status score of 2 or lower and relapsed or refractory mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma were enrolled and treated with voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity. The primary endpoint was the proportion of patients in each disease-specific cohort who achieved an overall response, defined as a complete response or partial response. All patients who received more than 4 weeks of treatment and who completed a baseline and at least one post-baseline tumour assessment were analysed for efficacy and all patients were analysed for safety. This study is registered with ClinicalTrials.gov, number NCT01403636, and has been completed. FINDINGS: Between Oct 19, 2011, and July 24, 2013, 167 patients were enrolled (42 with mantle cell lymphoma, 47 with follicular lymphoma, 42 with diffuse large B-cell lymphoma, and 36 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The median number of previous anticancer regimens was three (IQR 2-4) for patients with lymphoma and four (2-5) for patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Of 164 patients evaluable for efficacy, 30 (18·3%) achieved an overall response (partial, n=22; complete, n=8); 19 (41·3%) of 46 with follicular lymphoma, five (11·9%) of 42 with mantle cell lymphoma, two (4·9%) of 41 with diffuse large B-cell lymphoma, and four (11·4%) of 35 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The safety profile was consistent with that of previous studies of voxtalisib. The most frequently reported adverse events were diarrhoea (in 59 [35%] of 167 patients), fatigue (in 53 [32%]), nausea (in 45 [27%]), pyrexia (in 44 [26%,]), cough (in 40 [24%]), and decreased appetite (in 35 [21%]). The most frequently reported grade 3 or worse adverse events were anaemia (in 20 [12%] of 167 patients), pneumonia (in 14 [8%]), and thrombocytopenia (in 13 [8%]). Serious adverse events occurred in 97 (58·1%) of 167 patients. INTERPRETATION:Voxtalisib 50 mg given orally twice daily had an acceptable safety profile, with promising efficacy in patients with follicular lymphoma but limited efficacy in patients with mantle cell lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. FUNDING: Sanofi.
Authors: Johanna C Bendell; Jordi Rodon; Howard A Burris; Maja de Jonge; Jaap Verweij; Diana Birle; David Demanse; Stefan S De Buck; Qinhua C Ru; Malte Peters; Michael Goldbrunner; José Baselga Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater Journal: Leukemia Date: 2015-09-04 Impact factor: 11.528
Authors: Jennifer R Brown; Matthew S Davids; Jordi Rodon; Pau Abrisqueta; Siddha N Kasar; Joanne Lager; Jason Jiang; Coumaran Egile; Farrukh T Awan Journal: Clin Cancer Res Date: 2015-04-03 Impact factor: 12.531
Authors: Peiwen Yu; A Douglas Laird; Xiangnan Du; Jianming Wu; Kwang-Ai Won; Kyoko Yamaguchi; Pin Pin Hsu; Fawn Qian; Christopher T Jaeger; Wentao Zhang; Chris A Buhr; Paula Shen; Wendy Abulafia; Jason Chen; Jenny Young; Arthur Plonowski; F Michael Yakes; Felix Chu; Michelle Lee; Frauke Bentzien; Sanh Tan Lam; Stephanie Dale; David J Matthews; Peter Lamb; Paul Foster Journal: Mol Cancer Ther Date: 2014-03-14 Impact factor: 6.261
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Kyriakos P Papadopoulos; Josep Tabernero; Ben Markman; Amita Patnaik; Anthony W Tolcher; José Baselga; Weiliang Shi; Coumaran Egile; Rodrigo Ruiz-Soto; A Douglas Laird; Dale Miles; Patricia M Lorusso Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu Journal: Nature Date: 2015-10-14 Impact factor: 49.962